NEURIMMINFL/2014/003087

Myelin oligodendrocyte glycoprotein antibodies associate withanon-MS demyelination course in children

Yael Hacohen MRCPCH1, Michael Absoud MRCPCH PhD2, KumaranDeiva MD PhD3, Cheryl Hemingway MRCP PhD4, Petra Nytrova MD PhD5, Mark Woodhall PhD1, Jacqueline Palace MRCP MD1, Evangeline Wassmer FRCPCH 6, Marc Tardieu MD PhD3, Angela Vincent FRS FMed Sci1#, Ming Lim MRCP PhD1,2#, Patrick Waters PhD1# on behalf of United Kingdom Childhood Inflammatory Demyelination (UK-CID) and French Kidbiosep Study Groups.

1Nuffield Department of Clinical Neurosciences, JohnRadcliffeHospital, University of Oxford, Oxford, UK

2Children’s Neurosciences, Evelina Children's Hospital at Guy's and St Thomas' NHS Foundation Trust, King’s Health Partners Academic Health Science Centre, London, UK

3Assistance PubliqueHôpitaux de Paris, HopitauxUniversitaires Paris Sud, Pediatric Neurology Department and National Referral Center for Neuroinflammatory Diseases and Université Paris Sud, Le Kremlin-Bicêtre, Paris, France

4Department of Paediatric Neurology, GreatOrmondStreetHospital for Children, London, UK

5Department of Neurology and Center of Clinical Neuroscience, General University Hospital in Prague and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

6Department of Paediatric Neurology, Birmingham Children's Hospital, Birmingham, UK

# Joint senior authors

E Figure Caption

Figure e-1: Decision Classification tree using the χ2Automatic Interaction Detection (CHAID) growing method, based on Bonferroni adjusted significance testing. The regression tree analysishad a good predictive accuracy with the ROC curve analysis of predicted probabilities showing area under the curve being 0.97 (95% CI 0.93–0.99 p<0.001) and only 4 cases incorrectly predicted (1 MS and 3 non-MS). In the MOG-Ab positive node: ADS phenotype (ADEM or ON or TM) correctly predicted 100% of non-MS cases (20/20), whilst ADS phenotype (CIS-other than ON&TM) correctly predicted 67% (2/3) of MS cases. In the MOG-Ab negative node: the presence of periventricular lesions and GAD enhancing lesions correctly predicted 100% of MS cases (8/8); and the presence of periventricular lesions with absence of GAD enhancing lesions and absence of lesions in deep grey nuclei (thalamus and basal ganglia) correctly predicted non-MS cases in 71% (5/7). Also in the MOG-Ab negative node: the absence of periventricular lesions in CIS-other than ON and TM cases correctly predicted 100% (2/2), whilst the absence of periventricular lesions in ADEM or ON or TM cases correctly predicted non-MS cases in 96% (22/23). Abbreviations: ADEM acute disseminated encephalomyelitis; ADS acquired demyelinating syndromes; BG Basal Ganglia; CIS other clinically isolated syndromes; GAD Gadolinium; MOG-Ab myelin oligodendrocyte glycoprotein antibodies; MS multiple sclerosis; PV Periventricular TM transverse myelitis

1